Dr. Dormitzer joined GSK as Global Head of Vaccines Research and Development in December 2021. At GSK, he oversees a broad portfolio of Vaccine R&D programs. Previously, he was Chief Scientific Officer for Viral and RNA Vaccines at Pfizer, where he led programs that included the Pfizer-BioNTech RNA-based COVID-19 vaccine collaboration, which developed and distributed the world’s leading countermeasure against the COVID-19 pandemic. At both GSK and Pfizer, prefusion F-based RSV vaccines are in global phase 3 clinical trials. Previously, Dr. Dormitzer held positions at Novartis Vaccines that included Head of US Research. He was the founding member of the Novartis Viral Vaccine Research Center in Cambridge, MA. In 2009, his research team supported the development and licensure of three H1N1v influenza pandemic vaccines in what remains the most rapid vaccine response in history. In 2013, his team responded to the H7N9 influenza outbreak by supplying the US pre-pandemic stockpile with a vaccine generated from a synthesized virus, using techniques developed under contract with BARDA in collaboration with J. Craig Venter’s group. Before joining industry, Dr. Dormitzer was an Assistant Professor of Pediatrics at Harvard Medical School and led a structural virology laboratory, which, with collaborators, determined the structures of the rotavirus neutralization antigens. He graduated summa cum laude in Anthropology from Harvard College; conducted paleontological research in Pakistan and studied the Efe Pygmies in Zaire; obtained a Ph.D. in Cancer Biology and an MD at Stanford University; completed Internal Medicine training at Massachusetts General Hospital; and completed the Harvard Infectious Diseases Program clinical fellowship.